Management of Idiopathic Pulmonary Fibrosis

Introduction to IPF Management

The European Respiratory Society recommends initiating antifibrotic therapy with either pirfenidone or nintedanib in all patients with confirmed IPF who have mild-to-moderate disease, as these medications slow disease progression and reduce FVC decline 1.

Pirfenidone is approved for mild-to-moderate IPF at a dose of 2,403 mg/day divided into three doses with food, and both medications must be initiated and supervised by specialist physicians experienced in IPF diagnosis and management 1, 2.
Both medications slow disease progression, and their use should be guided by specialist physicians experienced in IPF diagnosis and management 1, 2.

The American Thoracic Society recommends administering annual influenza vaccination to all IPF patients, as well as providing pneumococcal vaccination using the polysaccharide pneumococcal vaccine, due to the high risk of respiratory infections in IPF patients 1, 3, 4.

The European Respiratory Society recommends prescribing long-term oxygen therapy for patients with severe hypoxemia at rest, and initiating a respiratory rehabilitation program in patients with significant exercise limitation and functional impairment 1, 3, 4.
Rehabilitation programs should include exercise training, smoking cessation, psychosocial assistance, and supportive care, and may improve walking distance, symptoms, and quality of life 3, 4.

The International Society for Heart and Lung Transplantation recommends considering lung transplantation in all patients aged <65 years with severe or worsening disease, and providing information about transplantation early in the disease course 1, 3, 4.
Transplantation improves survival in advanced IPF, and specific criteria include DLCO <39% predicted and FVC decline >10% over 6 months 3, 4.

The American Thoracic Society recommends diagnosing acute exacerbation when there is recent worsening of dyspnea (<30 days) with new lung opacities on imaging, after excluding infection, pulmonary embolism, and left heart failure 4, 5.
High-dose corticosteroids should be used as first-line treatment for acute exacerbations, despite limited controlled trial evidence, and consider intravenous cyclophosphamide as adjunctive immunosuppressive therapy 3, 4, 5.

IPF typically presents in patients over 60 years of age, predominantly male, with a history of cigarette smoking, and consider familial IPF and genetic predisposing factors in younger patients or those with family history of ILD 6, 7.
Evaluate and manage common comorbidities, including emphysema, lung cancer, pulmonary hypertension, sleep apnea, and coronary artery disease, and address gastroesophageal reflux disease, which is frequently present 7.